Invests in
Stages:
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Education
- Uo
- Uo
- CH
Lists including Wouter
Investments
Work Experience
2019
General Partner
2020
FEAC Board Director (NASDAQ now: ENGN)
2021 - 2023
De-SPAC with Engene, NASDAQ: ENGN
Partner
2019 - 2020
Board Member
2024
2024
Board Member
2024
Board Member (NASDAQ: NAMS)
2024
Board Member (Observer) (NASDAQ: NAMS)
2021 - 2024
2024
Board Member (NASDAQ: ENGN)
2024
2023
Board Member
2023
2023 - 2024
Board Member & Founding Investor - Sold to GSK for up to $1.4bn
2023 - 2024
2022 - 2023
Board Member (NASDAQ: VECT) - Sold to Ironwood for $1.2bn
2022 - 2023
2021 - 2022
Board Member - Sold to Novartis for up to $1.5bn
2021 - 2022
2016 - 2019
Executive Boardmember Life Sciences Franchise
2017 - 2019
Senior Life Sciences Trader
2016 - 2019
• Actively running Kempen’s Life Sciences portfolio • Specialized in European Life Sciences & Biotech • Involved in deal structuring, equity capital market transactions, crossing large blocks of company shares (for example placed >€150mln notional in Argenx at market levels in 2019), deal structuring through warrants/derivatives • Developed an extensive network with both corporates, and specialized investors